The COVID-19 pandemic has led to marked global morbidity and mortality. There have been appropriate but significant restrictions on routine medical care to comply with public health guidance on physical distancing, and to help preserve or redirect limited resources. Most invasive cardiovascular (CV) procedures and diagnostic tests have been deferred with North American cardiovascular societies advocating for intensified triage and management of patients on waiting lists. Unfortunately, patients with untreated cardiovascular disease are at increased risk of adverse outcomes5 . Delays in the treatment of patients with confirmed cardiovascular disease will be detrimental. Similarly, reduced access to diagnostic testing will lead to a high burden of undiagnosed cardiovascular disease that will further delay time to treatment. Although there will be a myriad of competing demands from multiple disciplines, this risk warrants the prioritization of cardiovascular patients as healthcare systems return to normal capacity.
You may also like
Comparison of Modified Chandler, Roller Pump, and Ball Valve Circulation Models for in vitro Testing in High Blood Flow Conditions: Application in Thrombogenicity Testing of Different Materials for Vascular Applications
Three different models, a modified Chandler loop, roller pump, and a new ball valve model (Hemobile), were compared with regard to intrinsic damage of blood components and activation of platelets.
Human Osteoblasts Attachment to Guided Tissue Regeneration Membranes Which Were Coated Either With Platelet-Rich Plasma or Platelet-Poor Plasma
To determine whether human alveolar bone osteoblasts (HABO) attachment to commercial available guided tissue regeneration (GTR) membranes can be enhanced by coating with freshly prepared human platelet-rich plasma (PRP) and platelet poor plasma (PPP).